New thiazolidinedione reduced the risk of cardiovascular complications in type 2 diabetes
A new drug from the thiazolidinedione group, lobeglitazone, reduced the risk of cardiovascular complications in patients with type 2 diabetes and ischemic stroke on a par with pioglitazone. At the same time, it did not increase the likelihood of heart failure.Researchers from Yeongseo University in Seoul compared the effectiveness of lobeglitazone and pioglitazone for the secondary prevention of cardiovascular complications in patients with ischemic stroke and type 2 diabetes. The study was published in the journal Cardiovascular Diabetology.
Lobeglitazone reduced the likelihood of cardiovascular complications by 26% and pioglitazone by 29%. The risk ratio was 1.05. At the same time, lobeglitazone did not increase the risk of heart failure (on the background of the drug the probability of developing the disease decreased by 10%), while pioglitazone increased this risk by 15%.
The study involved 83 thousand patients aged 20 years and older with type 2 diabetes who had an ischemic stroke. Repeated stroke, myocardial infarction and death from all causes within two years after stroke were recorded in 20 869 participants. Heart failure was diagnosed in 5,111 people.
Participants received pioglitazone or lobeglitazone. The risk of developing complications during drug therapy was assessed. The analysis considered gender, age, and risk factors for stroke, including hypertension, atrial fibrillation, coronary heart disease, kidney disease, and cancer. To assess safety, researchers analyzed the likelihood of developing heart failure when the drugs were prescribed.